Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Lifecell International Pvt. |
RCV003128169 | SCV003804184 | likely pathogenic | Migraine, familial hemiplegic, 3; Severe myoclonic epilepsy in infancy; Generalized epilepsy with febrile seizures plus, type 2; Developmental and epileptic encephalopathy 6B | criteria provided, single submitter | clinical testing | The splice region variant NM_001165963.4(SCN1A):c.2589+2dupT has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. The c.2589+2dupT variant is novel (not in any individuals) in gnomAD. The c.2589+2dupT variant is novel (not in any individuals) in 1kG. The nucleotide c.2589+2dupT in SCN1A is predicted conserved by GERP++ and PhyloP across 100 vertebrates; this variant is also predicted to be disrupted by NNSplice and PWM. Nearby regions of c.2589+2dupT; c.2589+1G>T (ClinVar ID: 372551) and c.2589+3G>T (ClinVar ID: 189938) are reported in ClinVar as pathogenic. For these reasons, this variant has been classified as Likely Pathogenic. | |
Mayo Clinic Laboratories, |
RCV004790481 | SCV005413511 | pathogenic | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | PP3, PM2_moderate, PS1 |